Primary Health Care Announces the Release of Determination by the Fair Work Commission

primary healthcare

Leading healthcare company in Australia, Primary Health Care Limited (ASX: PRY) announced that Fair Work Commission has released a decision and drafted workplace determination which is relating to support employees that includes Pathology collectors, Laboratory Assistants, Couriers, maintenance and store employees within Dorevitch. Company is not expecting the substance of the determination to change significantly.  [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

It is estimated that the determination is expected to have approximately a $4.5 million post-tax impact on UNPAT guidance for the year financial year 2019. Through a range of mitigation strategies, company is also aiming to fully offset the impact. It is estimated that the determination will have an impact of around $4.8 million. Primary is continuing to evaluate consequences of the determination within Dorevitch and other areas of its pathology division. Pathology division generally operates on a state-by-state basis, including different industrial instruments within each state. Company also acknowledges that the Commission has made some adverse remark about the Dorevitch’s historical approach of bargaining. This matter is taken seriously by the company and it has made number of changes at Dorevitch which includes appointment of new CEO. With the aim of promoting a better workplace culture Primary had taken several initiatives that includes a new Purpose mission and Values launched Group-wide over July and August 2018. The Share price of Primary Health Care slipped by 1.89% on 14 September 2018.

PRY shares traded at $2.845 with market capitalization of $1.69 billion as on 14 September 2018 (AEST 3:30 PM).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report